Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 476 - 500 of 15653 in total

P-nitrobiphenyl

Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.
Approved
Experimental
Investigational

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Iupac: … 4'-({2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl}methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl …
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …

Parthenolide

Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational

Methoxyphenamine

Approved
Matched Iupac: … [1-(2-methoxyphenyl)propan-2-yl](methyl)amine …

Fluticasone

Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … and proliferation. ... IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Butorphanol

A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved

Nalbuphine

A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Description: … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid …

Diflunisal

Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Description: … rheumatoid arthritis and osteoarthritis. ... Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. ... Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of …
Matched Categories: … Salicylic Acid and Derivatives …

Finasteride

Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase ... [L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo ... first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and …
Matched Categories: … doxazosin and finasteride ... alfuzosin and finasteride ... finasteride and tadalafil ... Skin and Mucous Membrane Agents ... Genito Urinary System and Sex Hormones …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved

Gluconic Acid

Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.
Approved
Investigational
Matched Description: … Commonly found in salts with sodium and calcium. …
Matched Mixtures name: … Normosol-R and Dextrose ... Plasma-Lyte 148 and dextrose ... Normosol-R and Dextrose …

Sarecycline

Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993,...
Approved
Investigational
Matched Iupac: … (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-{[methoxy(methyl)amino]methyl}-1,11-dioxo …
Matched Description: … the face but on the back and chest as well [L4814]. ... of hair follicles and their accompanying sebaceous glands [L4814]. ... to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona …

Cinoxacin

Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Approved
Investigational
Withdrawn
Matched Description: … Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections …

Loxoprofen

Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Matched Iupac: … 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid …
Matched Description: … , and as Oxeno in Argentina. ... It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India …
Matched Categories: … Topical Products for Joint and Muscular Pain …

Tyropanoic acid

Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image .
Approved
Matched Iupac: … 2-[(3-butanamido-2,4,6-triiodophenyl)methyl]butanoic acid …
Matched Description: … cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and …

Fenpropidin

Fenpropidin has been investigated for the treatment of Hernia.
Approved
Experimental
Matched Iupac: … 1-{2-[(4-tert-butylphenyl)methyl]propyl}piperidine …

Ritiometan

Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Approved
Matched Iupac: … 2-({bis[(carboxymethyl)sulfanyl]methyl}sulfanyl)acetic acid …

Pimethixene

Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.
Approved
Matched Iupac: … 1-methyl-4-(9H-thioxanthen-9-ylidene)piperidine …
Matched Description: … Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. …

Sitaxentan

Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn
Matched Iupac: … N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide …

Drometrizole trisiloxane

Drometrizole trisiloxane is a photostable UVA and UVB light filter [A33069, L2780, L2781, L2782, L2783, F81]. The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia, and Japan, among other countries....
Approved
Matched Iupac: … 2-(2H-1,2,3-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-(2,2,4,6,6-pentamethyl-3,5-dioxa-2,4,6-trisilaheptan …
Matched Description: … Drometrizole trisiloxane is a photostable UVA and UVB light filter [A33069, L2780, L2781, L2782, L2783 ... scientific record is not sufficient to establish the compound as being generally recognized as safe and ... sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia, and …
Matched Mixtures name: … Kiehls Activated Sun Protector Sunscreen SPF 50 For Face and Body For All Skin Types ... Kiehls Activated Sun Protector Sunscreen SPF 30 For Face and Body For All Skin Types …

Fezolinetant

Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Iupac: … 5-[(8R)-7-(4-fluorobenzoyl)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-3-methyl-1,2,4-thiadiazole …
Matched Description: … severe VMS daily have reported a decline in sleep quality, concentration, sexual activity, energy, and ... [A259606] Estrogen is a potent neuromodulator, particularly in the hypothalamus, and has been shown to ... increase neurokinin B signalling, increasing the activity of KNDy neurons and therefore the activity …
Matched Categories: … Genito Urinary System and Sex Hormones …

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Iupac: … 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2- …
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Iupac: … (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0 …
Matched Description: … combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and …

Guanadrel

Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Iupac: … N''-({1,4-dioxaspiro[4.5]decan-2-yl}methyl)guanidine …
Matched Description: … Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. …
Displaying drugs 476 - 500 of 15653 in total